Shire investors should snap up offer

Shire was London's top gainer after it rejected an approach by AbbVie of Chicago, the latest dealmaking attempt in the pharmaceutical industry. Lex’s Lucy Colback and Robert Armstrong discuss whether the offer undervalued Shire, as the Dublin-based company claims.